Sponsor content
844 result(s) found, displaying 451 to 460
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2021
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2021
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2021
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2021
-
Prescription medicine registrationActive ingredients: fluticasone propionate; salmeterol xinafoate.
-
Cancellation by sponsorRequested by Cipla Australia Pty Ltd
-
Cancellation by sponsorRequested by Cipla Australia Pty Ltd
-
Cancellation by sponsorRequested by Cipla Australia Pty Ltd
-
Cancellation by sponsorRequested by Cipla Australia Pty Ltd
-
Cancellation by sponsorRequested by Cipla Australia Pty Ltd